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Introduction
Non-small cell lung cancer (NSCLC) is the first leading cause of 
cancer-related death worldwide. Standard treatment of advanced 
disease is based on the combination of a platinum-derivative 
with a second drug such as gemcitabine, paclitaxel, pemetrexed, 
docetaxel or vinorelbine.1-5 Advanced NSCLC patients how-
ever, despite the treatment, have a median overall survival (OS) 
of about 10 mo.6 More recently, the efficacy of standard com-
bination chemotherapy has been improved by the introduction 
Bevacizumab is a humanized anti-VeGF monoclonal antibody able to produce clinical benefit in advanced non-squamous 
non-small cell lung cancer (nsCLC) patients when combined to chemotherapy. At present, while there is a rising attention 
to bevacizumab-related adverse events and costs, no clinical or biological markers have been identified and validated 
for baseline patient selection. preclinical findings suggest an important role for myeloid-derived inflammatory cells, such 
as neutrophils and monocytes, in the development of VeGF-independent angiogenesis. We conducted a retrospective 
analysis to investigate the role of peripheral blood cells count and of an inflammatory index, the neutrophil-to-
lymphocyte ratio (nLR), as predictors of clinical outcome in nsCLC patients treated with bevacizumab plus chemotherapy. 
one hundred twelve nsCLC patients treated with chemotherapy ± bevacizumab were retrospectively evaluated for the 
predictive value of clinical or laboratory parameters correlated with inflammatory status.
Univariate analysis revealed that a high number of circulating neutrophils and monocytes as well as a high nLR were 
associated with shorter progression-free survival (pFs) and overall survival (os) in bevacizumab-treated patients only. We 
have thus developed a model based on the absence or the presence of at least one of the above-mentioned inflamma-
tory parameters. We found that the absence of all variables strongly correlated with longer pFs and os (9.0 vs. 7.0 mo, hR: 
0.39, p = 0.002; and 20.0 vs. 12.0 mo, hR: 0.29, p < 0.001 respectively) only in nsCLC patients treated with bevacizumab 
plus chemotherapy.
our results suggest that a baseline systemic inflammatory status is marker of resistance to bevacizumab treatment in 
nsCLC patients.
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of anti-EGFR agents (in selected patients) and bevacizumab, an 
anti-angiogenic humanized monoclonal antibody (mAb) IgG1 to 
the vascular endothelial growth factor (VEGF).7 Two phase III 
trials showed the efficacy of this drug in non-squamous NSCLC 
patients;8-10 however, the use of this mAb is burdened by adverse 
events and unnecessary costs. A survival benefit was showed in 
the pivotal Sandler trial where bevacizumab was combined to 
carboplatin/paclitaxel doublets but not in the AVAIL trial when 
it was combined to cisplatin and gemcitabine. Furthermore, 
no clinical or biological markers for selection of patients, who 
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count lower than 600 cells/mm3 (p = 0.09) (Fig. 1C) and a NLR 
lower than 4 (p = 0.05) (Fig. 1D) experienced longer PFS only 
in the bevacizumab group. Furthermore, we found a significant 
association between a lymphocyte count lower than 1,700 cells/
mm3 at baseline and a worse response to chemotherapy (p = 0.02) 
(data not shown). On these findings, we developed a predictive 
model in which NSCLC patients were divided into two sub-
groups according to the absence or the presence of at least one of 
the above mentioned variables associated with better survival in 
the bevacizumab group. The absence of pro-inflammatory factors 
was significantly associated with better PFS in the bevacizumab 
group only (9.0 vs. 7.0 mo; HR: 0.39, 95% CI: 0.20–0.74; p = 
0.002) (Fig. 2). In the multivariate analysis (using forward step-
wise model) only the absence of “pro-inflammatory” factors 
continued to be significantly related to PFS (HR: 0.29, 95% CI: 
0.12–0.70; p = 0.006) in the bevacizumab group but not in the 
control group. Furthermore, we investigated our model on OS 
prediction (Fig. 3). Again, the same variable was highly corre-
lated with a better OS in the bevacizumab group only, regardless 
the short follow-up period. In the multivariate analysis (using 
forward stepwise model) only the absence of “pro-inflamma-
tory” factors remained significantly associated with OS (20.0 vs. 
12.0 mo; HR: 0.24, 95% CI: 0.09–0.63; p = 0.004).
Discussion
The present observational retrospective study suggests that the 
systemic inflammatory status at baseline, indirectly evaluated 
by measuring white blood cell counts, influences the outcome 
of patients with advanced NSCLC who receive a treatment con-
taining bevacizumab. In particular, we found that a specific pro-
file based on the concomitant presence of a low neutrophil and 
monocyte count and a low NLR was strongly associated with 
longer PFS and OS in patients treated with bevacizumab but not 
in control patients.
Currently, no clinical or biological factors predictive of resis-
tance to anti-VEGF treatment have been identified and patients 
are therefore exposed to unnecessary bevacizumab-related adverse 
effects of an expensive treatment. Gridelli et al. reviewed in a 
recent study15 the various retrospective and prospective analyses 
conducted on the E4599 and AVAIL trials in order to investigate 
possible clinical and laboratory predictive factors, underlining 
may benefit from bevacizumab-based treatments, are presently 
available.
Our research was based on pre-clinical and clinical findings 
on the inflammation-mediated cross-link between endothelial 
cells and innate immune system effectors11-13 which has been pro-
posed to play a critical role in the resistance to antiangiogenic 
treatments. In particular, inflammatory cells that enrich tumor 
micro-environment trigger tumor progression and escape from 
immune system, as well as they induce a VEGF-independent 
angiogenesis.14 On these results, we hypothesized that changes 
in the systemic inflammatory status, measured trough periph-
eral blood cell counts and neutrophil to lymphocyte ratio (NLR), 
may reflect changes in tumor inflammatory microenvironment, 
providing useful information on the potential activation of alter-
natives pathways of angiogenesis which may account for impair-
ment of bevacizumab activity.
We conducted a retrospective study with the purpose of inves-
tigating the role of peripheral lymphocyte, neutrophil, monocyte 
and platelet counts and of an inflammatory index, the NLR, as 
predictors of the clinical outcome of NSCLC patients treated 
with bevacizumab in addition to first-line platinum based com-
bination chemotherapy.
Results
Patients’ characteristics. Patients’ characteristics at baseline are 
shown in Table 1. A total of 112 patients were included in our 
study (median age 62 ± 11 y; male 72%). 73 received a standard 
platinum-based doublet plus bevacizumab, while 39 received the 
platinum-based chemotherapy alone and were used as a calibration 
arm. No significant differences were observed between baseline 
characteristics of two groups. Median follow-up time was 15 mo. 
We observed a RR of 66.7 and 45.2% and a disease control rate 
(DCR) of 88.9% and of 71% for the bevacizumab group and the 
group respectively. The median PFS of the whole group was 7 mo 
(95% CI: 6.17–7.82 mo) (Fig. 1A), while the median OS was 
15 mo (95% CI: 13.23–16.77 mo). PFS and OS were not signifi-
cantly different between the bevacizumab and the control group.
Univariate and multivariate analysis. We analyzed the effect 
of the above mentioned 8 potential prognostic variables on PFS 
(Table 2). In our analysis, patients with a basal neutrophil count 
lower than 7,000 cells/mm3 (p = 0.02) (Fig. 1B), a monocyte 
Table 1. Baseline characteristics
CHT + BEV (n = 73) Control group (n = 39)
Age (mean ± sd), years 58.57 ± 10.54 67.85 ± 9.67
sex (male/female), % 75/25 67/33
eCoG (median) 0 0
histology (Ad/sq/Und), % 79.5/15.1/5.5 79.5/12.8/7.7
neutrophil counts (mean ± sd/mm3) 6400 ± 2800 5800 ± 2000
Lymphocyte counts (mean ± sd/mm3) 1900 ± 1300 1800 ± 990
Monocyte counts (mean ± sd/mm3) 560 ± 270 540 ± 260
platelets counts (mean x 103 ± sd/mm3) 285 ± 102 276 ± 105
nLR (mean ± sd) 4.62 ± 3.97 3.78 ± 1.96
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com Cancer Biology & Therapy 471
Neutrophils are recruited at the site of inflammation or 
tumor from the peripheral blood and different immune-
histochemistry studies have shown increased neutrophil num-
ber in human tumors compared with healthy tissues.19-21 Indeed 
several tumor transplant models as well as mouse models of 
tumor development demonstrated that neutrophils are able to 
promote angiogenesis by releasing different proangiogenic fac-
tors such as VEGF, IL-8 and Bv8 or protease such as MMP-9 
and to trigger the angiogenic-switch, an essential step for tumor 
progression.14,22-25 Furthermore, in a recent xenograft study, 
Shojaei et al. reported increased levels of granulocyte colony 
stimulating factors (G-CSF) and Bv8 in mice bearing tumors 
refractory to anti-VEGF treatment thus confirming the essen-
tial role of polymorphonucleated cells in VEGF-independent 
angiogenesis.26
that, to date, no clinical or biological markers are reliable can-
didate for validation and translation in clinical practice. More 
recently Mok et al., in an exploratory analysis to investigate pos-
sible correlation between different biomarker associated with 
angiogenesis (such as FGF, E-selectin, PIGF, VEGF and VEGF 
receptors) and RR, failed to find any statistically significant asso-
ciation.16 However, none of these analyses included evaluation of 
pre-treatment leukocyte subpopulations.
On the other hand, different preclinical models suggest that 
tumor infiltration by bone marrow-derived inflammatory cells 
is involved in resistance to antiangiogenic therapy.17 These cells, 
attracted in the tumor tissue by different stimuli such as hypoxia 
and/or necrosis, may in turn lead to the development of both 
VEGF dependent or independent neo-angiogenesis; the latter is 
not affected by bevacizumab.18
Figure 1. progression free survival estimation of the whole group (A) and according to baseline neutrophil (B) and monocyte (C) count and nLR 
value (D) in nsCLC patients treated with bevacizumab.
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a low NLR value and longer PFS and OS in patients with meta-
static renal cell carcinoma treated with the anti-VEGF receptor 
sunitinib.31 These results are similar to those we found in CRC 
patients receiving bevacizumab in front-line therapy, where a low 
baseline NLR value was associated with the longest PFS, mir-
roring the results of the present study and underscoring the rel-
evance of systemic inflammatory status as marker of resistance to 
bevacizumab-treatment.32 Of interest, Yao et al. found a prognos-
tic role for pretreatment NLR in NSCLC patients treated with 
first-line platinum-based chemotherapy.33 However, this result 
was not confirmed in our calibration group, probably because of 
the small sample of patients included.
NLR may also represent an indicator of the balance between 
neutrophils and lymphocytes, reflecting patients’ immune-status. 
Host’s immune response to cancer cells is in fact lymphocyte-
dependent and different studies reported association between 
low or high lymphocyte count and survival.34,35 Interestingly, 
we found in the control group an advantage in term of PFS 
for patients who presented a high baseline lymphocyte count; 
Monocytes are attracted in tumor tissue by different chemo-
kines, such as CCL-2 or CCL-5, produced by cancer cells, fibro-
blasts or immune cells. Once have reached the tumor site, these 
cells quickly differentiate into tumor-associated macrophages 
(TAMs). TAMs could, under certain conditions, switch to a 
so-called tumor promoting M2-like macrophage polarization, 
express Tie-2 marker and induce angiogenesis through secretion 
of different pro-angiogenic factors such as VEGF, IL-8, FGF and 
MMP-9.27,28
NLR represents a marker of systemic inflammation found to 
be associated with prognosis in different malignancies. Cedrès et 
al. found a direct association between a high NLR value and poor 
prognosis in NSCLC patients. Furthermore, they discovered that 
patients whose NLR normalize during chemotherapy showed 
improved survival.29 These results are in line with our findings in 
colorectal cancer (CRC) where we observed an improved survival 
in patients who experienced a reduction in NLR along the treat-
ment, compared with those who maintained high NLR values.30 
Additionally, Keizman et al. reported on the association between 
Table 2. Univariate analysis
Variables BEV group Control group
PFS HR (95% CI) p value PFS HR (95% CI) p value
Age
 < 65 y 7.0
0.68 (0.36–1.29) 0.25
4.4
0.74 (0.31–1.77) 0.48
 > 65 y 8.0 7.0
Sex
F 7.0
0.83 (0.33–2.07) 0.72
7.0
0.90 (0.51–1.61) 0.68
M 7.9 6.0
Histology
Ad 8.0
0.93 (0.59–1.47) 0.85
6.0
0.93 (0.46–1.89) 0.90sq 7.0 11.0
Und 2.0 9.0
Neutrophil counts
 < 7,000 cells/mm3 8.0
1.80 (1.06–3.07) 0.02
9.0
1.49 (0.57–3.85) 0.39
 > 7,000 cells/mm3 6.0 4.0
Lymphocyte counts
 < 1,700 cells/mm3 7.0
1.06 (0.64–1.74) 0.88
4.43
0.36 (0.14–0.93) 0.02
 > 1,700 cells/mm3 7.4 11.0
Monocyte counts
 < 600 cells/mm3 8.0
1.51 (0.90–2.54) 0.09
7.0
0.73 (0.28–1.90) 0/50
 > 600 cells/mm3 7.0 7.0
Platelets counts
 < 400 × 103 cells/mm3 5.0
1.12 (0.47–2.66) 0.78
6.0
0.44 (0.13–1.53) 0.17
 > 400 × 103 cells/mm3 7.0 12.0
NLR
 < 4 8.0
1.67 (1.00–2.80) 0.05
7.0
1.68 (0.69–4.07) 0.23
 > 4 7.0 6.0
Pro-inflammatory factors
0 9.0
0.39 (0.20–0.74) 0.002
7.0
1.14 (0.48–2.70) 0.75
At least 1 7.0 7.0
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Patients and Methods
Patients. Seventy-three consecutive patients with advanced 
(IIIB/IV stage) NSCLC who underwent first line treatment 
with a platinum-based doublet plus bevacizumab in five Italian 
medical oncology units (Siena, Catanzaro, Naples, Avellino and 
Frattamaggiore), between 2008 and 2011, were retrospectively 
reviewed. We evaluated patients who participated in clinical trials 
(phase II/III trials).42-44 Thirty-nine advanced NSCLC patients 
from the same medical centers, treated with chemotherapy 
alone, were included in our analysis as a control arm. Data were 
extracted from patient medical records. Data collected for our 
analysis included: age, gender, pathological confirmed diagnosis 
of NSCLC, performance status, pre-treatment laboratory find-
ings (in particular neutrophil, lymphocyte, monocyte and plate-
let counts), treatment outcomes in terms of response rate (RR), 
progression free survival (PFS) and OS. In the experimental arm, 
bevacizumab was administered according to the protocol of the 
different clinical trials (dose range 5–15 mg/kg every 3 weeks). 
In both groups chemotherapy was administered for 4–6 cycles 
every three weeks or until progression or death or in the presence 
of unacceptable toxicities. The response was assessed according to 
Response Evaluation Criteria in Solid Tumors (RECIST) version 
1.1. The study was performed according to bioethic standards of 
participating Institutions and patients had provided consent to 
data management at trial enrollment.
Statistical analysis. All patients were evaluated for PFS and 
OS. PFS was defined as time from enrollment to progression dis-
ease or death, while OS was defined as time from enrollment 
to death. Both PFS and OS were considered primary endpoints. 
All potential prognostic factors were transformed into categori-
cal variables. Patients were grouped as male vs. female, squa-
mous cell carcinoma vs. adenocarcinoma, > 7,000 vs. < 7,000 
cells/mm3 neutrophils count (upper limit of normal), > 1,700 
however due to the low size of the group no definitive conclu-
sion could be drawn. Moreover, previous results by our group 
suggested that basal tumor infiltration by both T
CCR7
 and T
reg
 
lymphocyte is predictive of favorable outcome in metastatic CRC 
patients and that chemo-immunotherapy may modulate patients’ 
own immune-response.36-39 We believe that these findings under-
line the central role of the interplay between inflammation, 
angiogenesis and immune system in conditioning cancer patients’ 
survival and response to treatment supporting the potential role 
of chemo-immunotherapy in NSCLC.40,41
Our study presents some limitations such as the low number of 
enrolled patients especially in the control/calibration group, the 
lack of a validation data set in an independent patient cohort con-
tributing to the preliminary character of this report. Furthermore, 
other inflammatory index such as reactive C protein (RCP) or 
erythrosedimentation velocity (ESV) as well as plasma inflam-
matory cytokines are not routinely measured in NSCLC patients 
and we could evaluate their impact on the selected outcomes in 
prospective studies only. Despite these weaknesses, we believe that 
the number of neutrophils and monocytes in the peripheral blood 
as well as NLR may reflect the pro-angiogenic/pro-inflammatory 
status in tumor tissue, thus leading us to potential identification 
of patients carriers of tumors that constitutively express different 
pro-angiogenic pathways, potentially independent from VEGF. 
These patients, most likely, will not gain any benefit from the 
addition of bevacizumab to chemotherapy consistent with our 
study results indicating lack of bevacizumab benefit in patients 
with elevated systemic inflammatory markers. We conclude that 
our study provide a proof of principle that baseline inflammatory 
status might play an important role in the selection of NSCLC 
patients candidate to bevacizumab. Further studies are needed to 
validate our model in larger prospective series and to shed light 
on the molecular mechanisms underlying the strong association 
between inflammation and angiogenesis.
Figure 2. progression free survival probability according to the baseline inflammatory status (neutrophil count > 7,000 cells/mmc, monocyte count 
> 600/mmc, nLR > 4; see text) in nsCLC patients treated with (A) or without (B) bevacizumab.
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
474 Cancer Biology & Therapy Volume 14 issue 6
significant variables were entered in the model through a step-
wise method. The analysis was performed through SPSS version 
17 statistical package.
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vs. < 1,700 cells/mm3 lymphocytes count (lower limit of nor-
mal), > 600 vs. < 600 cells/mm3 monocytes count (upper limit 
of normal), > 400 × 103 vs. < 400 × 103 cells/mm3 platelets count 
(upper limit of normal), < 4 vs. > 4 NLR (measured as the ratio 
between neutrophil and lymphocyte counts at baseline) (mean of 
the group). Survival curves and medians were estimated with the 
Kaplan-Meier method and the association between each variable 
and survival was assessed by logrank test in univariate analysis. 
Variables with a p value lower than 0.10 were used to construct a 
predictive model. The Cox proportional hazard model was used 
subsequently in the multivariate analysis to assess the contribu-
tion of each potential prognostic factor to survival. The most 
Figure 3. overall survival estimation according to the baseline inflammatory status (neutrophil count > 7,000 cells/mmc, monocyte count > 600/mmc, 
nLR > 4; see text) in nsCLC patients treated with (A) or without (B) bevacizumab.
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